Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 14.3% in June

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large decrease in short interest in June. As of June 15th, there was short interest totalling 42,400 shares, a decrease of 14.3% from the May 31st total of 49,500 shares. Currently, 4.9% of the shares of the company are short sold. Based on an average trading volume of 60,600 shares, the days-to-cover ratio is presently 0.7 days.

Avenue Therapeutics Stock Performance

Shares of NASDAQ ATXI traded down $0.08 during midday trading on Friday, reaching $3.50. The stock had a trading volume of 49,885 shares, compared to its average volume of 22,430. Avenue Therapeutics has a 12-month low of $3.25 and a 12-month high of $93.75. The stock has a 50-day moving average of $4.27 and a 200-day moving average of $9.02. The company has a market capitalization of $3.29 million, a price-to-earnings ratio of -0.44 and a beta of -0.10.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($15.40) EPS for the quarter.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.